A member of a key CDC advisory board told CNBC Friday morning that he expects the U.S. hiatus on Johnson & Johnson’s one-off coronavirus vaccine to be lifted at some point.
“I think we are ready to use this vaccine. We had to take an important pause to review this safety information in order to consider the risks. But I think there is a large amount of evidence that the Benefit far outweighs this risk, “said Dr. Wilbur Chen, professor in the University of Maryland School of Medicine.
Chen spoke on “Worldwide Exchange” hours before attending a meeting of the Agency’s Advisory Committee on Immunization Practices late Friday to discuss the rare but serious bleeding disorder some women had after receiving the J&J shot.
In addition to the six patients who experienced rare but severe blood clotting problems after receiving the vaccine, the CDC is investigating two other possible cases: a deceased woman from Oregon and a hospitalized woman from Texas. Of the original six women, one died and one became seriously ill. Approximately 8 million J&J vaccine doses have been administered.
Concerns about the issue prompted the Center for Disease Control and Prevention and the FDA to temporarily suspend use of the J&J vaccine in the U.S. last week. When asked by CNBC’s Brian Sullivan whether he believes Americans will eventually get the J&J vaccine, Chen said, “Yes.”
The Advisory Committee on Immunization Practices, known as ACIP, is an external panel of experts that makes recommendations to the CDC. A meeting on the J&J vaccine was called last week, but a decision was postponed until this week. Ultimately, it is up to the CDC and the Food and Drug Administration what to do next.
Chen said ACIP now has better information about the blood clotting problems on which to base its vaccination instructions. “We’ll be able to get a good sample size. It might not be perfect, but we don’t have to be perfect to have actionable information,” he said, expecting the panel to “come up with a number of recommendations that I do think everyone will be happy with. “
In a statement emailed to CNBC, CDC Director Dr. Rochelle Walensky announced that the Public Health Agency would receive a “recommendation” that considers the risk versus reward of using the Johnson & Johnson vaccine based on the new case data and risk. Benefit analysis CDC has conducted over the past week. ”
“I really appreciate the complex issue before the committee and look forward to hearing from you. I also appreciate the importance of working quickly with the FDA as soon as we hear about ACIP,” added Walensky .
Given the urgency of the pandemic, some people have criticized the decision to discontinue the J&J Covid vaccine – which only requires one dose for full immunity protection – while the clot screening was going on.
“The risk is very, very small, but until we could fully take into account this information, we haven’t been able to contextualize this for the rest of the medical community, including the public,” he said. “We only took a 10-day break. Hopefully this will not be harmful in the long term, but of course we want to instill confidence in the system for collecting safety information.”
The other two emergency Covid vaccines approved in the United States come from Pfizer and Moderna. Both require two shots.